InMed Pharmaceuticals Inc (INM)

[greenwillow]

January is National #Glaucoma Month - raising awareness of a leading cause of blindness in the world. Using #cannabinoids to treat the disease is well-known, but surprisingly no product exists! Read more about how INM-085 can fill the gap here:

https://www.inmedpharma.com/pipeline/inm085/

Glaucoma is a chronic optic neuropathy that is typically caused by high intraocular pressure, or IOP. Inadequate or obstructed drainage of the aqueous humor through the trabecular mesh, which is the pathophysiology of glaucoma, increases the fluid pressure within the anterior chamber, subsequently propagating into the posterior chamber of the eye, according to Weinreb et al.’s, 2014 article “The pathophysiology and treatment of glaucoma: a review”. The increased intraocular pressure exacts a toll on the basal membrane of the retina, thinning the mesh-like tissue in this region and damaging the head of the optic nerve. According to Quigley and Boman’s 2006 publication “The number of people with glaucoma worldwide in 2010 and 2020”, glaucoma is currently the second leading cause of blindness world-wide; it is estimated to affect a population close to 80 million by 2020.

January is National #Glaucoma Month- raising awareness of a leading cause of blindness in the world. Using #cannabinoids to treat the disease is well-known, but surprisingly no product exists! Read more about how INM-085 can fill the gap here:... https://t.co/mzSSSUIH4V

— InMed Pharmaceuticals (@inmedpharma) January 15, 2019